Steven Cohen's LYEL Position Overview
Steven Cohen (via Point72 Asset Management, L.P.) currently holds 26,080 shares of Lyell Immunopharma, Inc. (LYEL) worth $366,424, representing 0.00% of the portfolio. First purchased in 2025-Q4, this short-term holding has been held for 3 quarters.
Based on 13F filings, Steven Cohen has maintained this position in LYEL for several quarters, showing initial confidence in the investment. Largest addition occurred in Q1 2026, adding 9,812 shares.
Analysis based on 13F filings available since 2013 Q2
Steven Cohen's Lyell Immunopharma (LYEL) Holding Value Over Time
Track share changes against reported price movement
Quarterly Lyell Immunopharma (LYEL) Trades by Steven Cohen
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q2 2026 | +4,788 | Add 22.49% | 26,080 | $14.05 |
| Q1 2026 | +9,812 | Add 85.47% | 21,292 | $20.06 |
| Q4 2025 | +11,480 | New Buy | 11,480 | $30.78 |
Steven Cohen's Lyell Immunopharma Investment FAQs
Steven Cohen first purchased Lyell Immunopharma, Inc. (LYEL) in Q4 2025, acquiring 11,480 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Steven Cohen has held Lyell Immunopharma, Inc. (LYEL) for 3 quarters since Q4 2025.
Steven Cohen's largest addition to Lyell Immunopharma, Inc. (LYEL) was in Q4 2025, adding 11,480 shares worth $353,354.
According to the latest 13F filing for Q2 2026, Steven Cohen's firm, Point72 Asset Management, L.P., owns 26,080 shares of Lyell Immunopharma, Inc. (LYEL), valued at approximately $366,424.
As of the Q2 2026 filing, Lyell Immunopharma, Inc. (LYEL) represents approximately 0.00% of Steven Cohen's publicly disclosed stock portfolio, making it one of their key holdings.
Steven Cohen's peak holding in Lyell Immunopharma, Inc. (LYEL) was 26,080 shares, as reported at the end of Q2 2026.